1998
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceBiomarkers, TumorBreast NeoplasmsCohort StudiesCytosolFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedPloidiesPrognosisProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneS PhaseSurvival AnalysisTime FactorsUnited StatesConceptsProstate-specific antigenPrimary breast cancerBreast cancerCohort studyPrognostic valueRelative riskBreast tumorsSteroid hormone receptor levelsLow S-phase fractionMeasurement of PSAPSA-negative patientsPSA-positive patientsPrognosis of patientsYounger patient ageHormone receptor levelsLarge cohort studyUnited States cohort studyValuable tumor markerS-phase fractionUnited States patientsBreast tumor extractsMedian followPSA presenceNodal statusPatient age
1996
Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samplesCreatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.Peer-Reviewed Original ResearchConceptsCK-BB levelsCK-BBTumor cytosolsEstrogen receptor-negative cancersEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancer patientsRisk of deathReceptor-negative cancersRisk of relapseBreast tumor cytosolsHistological typeClinicopathological variablesPatient survivalPrognostic indicatorTumor stageAggressive tumorsCancer patientsProgesterone receptorUnivariate analysisHigh riskBB groupIsoenzyme levelsPatientsBreast tumors
1995
Prostate-specific antigen in serum of women with breast cancer
Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque M, Diamandis E. Prostate-specific antigen in serum of women with breast cancer. British Journal Of Cancer 1995, 72: 728-731. PMID: 7545417, PMCID: PMC2033864, DOI: 10.1038/bjc.1995.401.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenBreast cancer patientsBreast cancerPSA levelsCancer patientsTumor cytosolsBreast tumorsPSA concentrationFree prostate-specific antigenSerum of womenFavorable prognostic indicatorSerum PSA levelsNormal male serumFemale breast tumorsBreast cancer diagnosisPresurgical seraPrognostic indicatorSurgical removalNormal breastMale serumCancerSerumCancer diagnosisTumorsQuantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique
Zarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.Peer-Reviewed Original ResearchConceptsCK-BB levelsBreast tumor cytosolsCreatine kinase BBCK-BBProstate cancerTumor cytosolsCancer patientsEstrogen sensitivityHealthy subjectsSerum CK-BB levelsActive prostate cancerSensitive immunofluorometric procedurePost-radical prostatectomyProstate cancer patientsSerum CK-BBCK-BB isoenzymeSteroid hormone receptorsSerum PSAProgesterone receptorRadical prostatectomyBreast cancerMale volunteersHealthy volunteersPatientsBreast tumorsProstate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage
1994
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene product